Compass Point’s Max Reale talks the impact of a possible FDA ban on compounded GLP-1 offerings

Max Reale, Compass Point head of policy research, joins ‘Closing Bell Overtime’ to talk the current state of the weight-loss drug space and the impact of a possible compounded GLP-1 ban.